PureTech Health (PRTC) Cash & Equivalents (2019 - 2025)

PureTech Health (PRTC) has 6 years of Cash & Equivalents data on file, last reported at $277.3 million in Q4 2025.

• Quarterly Cash & Equivalents fell 24.5% year-over-year to $277.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $277.3 million (down 24.5% YoY) and the FY2025 annual result came in at $277.3 million, down 24.5% from the prior year.
• Cash & Equivalents grew to $277.3 million in Q4 2025 per PRTC's latest filing, from $260.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $465.7 million in Q4 2021 and bottomed at $149.9 million in Q4 2022.
• The 4-year median for Cash & Equivalents is $277.3 million (2025), against an average of $304.2 million.
• The widest annual swing landed in 2021, when Cash & Equivalents climbed 15.31%; it then slumped 67.82% in 2022.
• Tracing PRTC's Cash & Equivalents over 4 years: stood at $465.7 million in 2021, then tumbled by 67.82% to $149.9 million in 2022, then soared by 145.09% to $367.3 million in 2024, then fell by 24.5% to $277.3 million in 2025.
• Per Business Quant, the three latest PRTC Cash & Equivalents figures stand at $277.3 million (Q4 2025), $260.6 million (Q2 2025), and $367.3 million (Q4 2024).

Peer Comparison